Celltrion Healthcare (091990.KQ)

Overall impact
B (65)

Commentary

Celltrion Healthcare is a strong overall performer. With a 'B' rating of 64.6 for overall impact (72nd percentile compared to all companies), Celltrion Healthcare ranks 351st out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 347 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 231 others. On top material causes for Celltrion Healthcare's industry (Pharmaceuticals & Biotech), Celltrion Healthcare performs well in Child and Maternal Health (86.6 score), Child and Maternal Health (95.0), Disease Eradication (96.4) and 2 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (33.9 score), Decent, Safe Work Opportunities (35.4) and Sustainable Use of Water (31.7).
Impact
Cause 091990.KQ
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1999
Employees
158
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
South Korea
Share classes
091990.KQ
Description
Celltrion Healthcare Co Ltd markets, sells and distributes biosimilar and biological medicines developed by the company through extensive global network that covers more than 120 different countries, including both developed and emerging markets.
Material causes
Ethos considers the following causes material for Celltrion Healthcare, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.